SeeTrue Technologies raises €2.2M to shrink eye-tracking into the next generation of smart glasses

SeeTrue Technologies (Joensuu) has raised €2.2 million in a financing round led by ZEISS Ventures, the corporate venture arm of Carl Zeiss AG. Superhero Capital, North Karelia Growth Fund (NKGF) via Redstone Nordics, and Luminate — the optics-sector accelerator backed by ZEISS and the University of Rochester — also participate, alongside Finnish angel investors. The company was founded in 2018 by Roman Bednarik as a spinout from the University of Eastern Finland, where Bednarik led eye-tracking research for two decades. No explicit funding stage is stated in the announcement.

The constraint nobody has solved cheaply

Eye-tracking works well where a device can afford to power it. PC-class VR headsets — enterprise rigs and Meta Quest Pro-class hardware — have the battery headroom and thermal budget that conventional sensor-and-processor architectures require. The problem is different for the thin-frame consumer glasses market that every major optics and technology company is pursuing: frames light enough to wear all day, with batteries measured in hours, cannot run current eye-tracking implementations without draining in under an hour.

SeeTrue's central claim is an ultra-miniature, ultra-low-power eye-sensing architecture that can fit inside a normal-looking pair of glasses without dominating its power budget. The company describes this as an architectural reinvention — a sensor pipeline designed from the physics up for the thermal and power constraints of wearable frames, rather than a conventional design adapted after the fact. The use cases are well-established: foveated rendering (which reduces GPU load sharply by rendering in full resolution only where the eye is pointed), gaze-based interaction, user authentication, and — in the medical variant — ophthalmic diagnostic measurement.

ZEISS Ventures leading the round is the most credible external validation the company could attract. ZEISS supplies optics to the spectacles and precision-imaging markets globally, and is directly involved in the lens systems for multiple AI-glasses programmes. The corporate venture arm does not lead early-stage financing rounds routinely; when it does, the working assumption is that the investment is on a path toward a development or supply relationship, not simply financial.

Two markets, one architecture

The capital funds three things: commercial expansion of the current architecture, engineering team growth in Joensuu, and new partnerships across both consumer wearables and medical optical systems. The medical track is not secondary: ophthalmic exam equipment and near-eye diagnostic devices that track gaze or measure ocular-motor function represent a parallel revenue path, less dependent on XR hardware adoption timelines. Luminate, whose portfolio spans optics applications across medical, industrial, and consumer segments, adds commercial reach on that side.

"We aren't just improving eye tracking; we are shrinking it to fit the future of wearable tech," said Bednarik. "If XR and AI glasses are supposed to achieve mass adoption, eye-tracking must become invisible to the user but significantly more powerful for the device."

What the next 18 months must show: whether the architecture reaches integration in a named commercial product, and whether the ZEISS relationship converts from investor to development partner. The technical claims have not been independently validated publicly — performance under real-world wearable constraints remains unverified outside the company. Joensuu sits outside Finland's main deep-tech clusters in Helsinki and Espoo; scaling a hardware company from that base, in a discipline that requires chip-design and photonics expertise, is a material execution risk that a €2.2 million round has to fund alongside the commercial work.